Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences IncfiledCriticalGilead Sciences Inc
Publication of DOP2017000174ApublicationCriticalpatent/DOP2017000174A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporcionan en el presente documento métodos que se relacionan con una estrategia terapéutica para el tratamiento del cáncer, incluyendo malignidades hematológicas. En particular, los métodos incluyen la administración de entospletinib y un inhibidor de Bcl-2, tal como venetoclax, navitoclax y ABT-737.Methods that relate to a therapeutic strategy for the treatment of cancer, including hematological malignancies, are provided herein. In particular, the methods include administration of entospletinib and a Bcl-2 inhibitor, such as venetoclax, navitoclax and ABT-737.
DO2017000174A2015-02-032017-07-28
COMBINATION THERAPIES FOR CANCER TREATMENT
DOP2017000174A
(en)
PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION AND / OR TREATMENT OF DISEASES THAT ARE DEVELOPED OR PROGRESSED AS A RESULT OF A DECREASE OR LOSS OF ACTIVITY OF THE ACTIVATED BLOOD COAGULATION VIII.